This site is intended for healthcare professionals

Představení titulu

Novinky z letošního nejvýznamnějšího setkání onkologů 2017

Originální název:
Novinky z letošního nejvýznamnějšího setkání onkologů

Datum vydání: 09/2017


Formát: 210×270 mm

Počet stran: 120

Vazba: V1 ?Listy jsou spojeny sponkou ve hřbetu

Jazyk: čeština

Náhled PDF


Anotace

Publikace přináší souhrnnou informaci o nejdůležitějších sděleních týkajících se karcinomů gastrointestinálního traktu, genitourinárních nádorů, karcinomu prsu, gynekologických malignit, nádoru plic a melanomu. Prezentace zazněly na kongresu Americké společnosti klinické onkologie, který proběhl ve dnech 2.–6. června 2017 v Chicagu.



Obsah

VYBRANÉ NOVINKY ZAMĚŘENÉ NA ZHOUBNÉ NÁDORY ZAŽÍVACÍHO TRAKTU
Luboš Petruželka
 
Post-Surgery Capecitabine ‘Should Become Standard of Care’ in Biliary Tract Cancers
Michelle Dalton
 
SOMATIC DNA MUTATIONS, MSI STATUS, MUTATIONAL LOAD (ML): ASSOCIATION WITH OVERALL SURVIVAL (OS) IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) OF CALGB/SWOG 80405 (ALLIANCE)
Federico Innocenti, Fang-Shu Ou, Tyler Zemla, Donna Niedzwiecki, Xueping Qu, Rachel Tam, Shilpi Mahajan, Richard M. Goldberg, Robert J. Mayer, Monica M. Bertagnolli, Hanna Kelly Sanoff, Howard S. Hochster, Charles David Blanke, Alan P. Venook, Heinz-Josef Lenz, Omar Kabbarah
 
ONCOLOGICAL BENEFIT OF PARENCHYMA-PRESERVING HEPATECTOMY FOR COLORECTAL LIVER METASTASIS
Isamu Hosokawa, Marc Antoine Allard, Hidetoshi Nitta, Real W. Lapointe, Darius Mirza, Gennaro Nuzzo, Eduardo Barroso, Gernot Kaiser, Catherine Hubert, Lorenzo Capussotti, Graeme John Poston, Irinel Popescu, Santiago Lopezben, Jan N.M. IJzermans, Jean-Francois Ouellet, Mauro Salizzoni, Derek Oreilly, Oleg Skipenko, René Adam
 
Risk-Based Approach to Chemotherapy Duration Recommended for Stage III Colon Cancer
Tim Donald
 
Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)
Alan P. Venook, Fang-Shu Ou, Heinz-Josef Lenz, Omar Kabbarah, Xueping Qu, Donna Niedzwiecki, Tyler Zemla, Richard M. Goldberg, Howard S. Hochster, Bert H. O‘Neil, Hanna Kelly Sanoff, Robert J. Mayer, Monica M. Bertagnolli, Charles David Blanke, Federico Innocenti
 
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer
Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia Ibrahim Jalal, Manish A. Shah, Jean-Philippe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A. Wainberg, Daniel V.T. Catenacci, Yung-Jue Bang, Jiangdian Wang, Minori Koshiji, Rita P. Dalal, Harry H. Yoon
 
Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study
Yelena Yuriy Janjigian, Patrick Alexander Ott, Emiliano Calvo, Joseph W. Kim, Paolo Antonio Ascierto, Padmanee Sharma, Katriina Johanna Peltola, Dirk Jaeger, T.R. Jeffry Evans, Filippo G. De Braud, Ian Chau, Marina Tschaika, Christopher T. Harbison, Weiguo Cai, Johanna C. Bendell, Dung T. Le
 
GENITOURINÁRNÍ SEKCE ASCO 2017
Jindřich Fínek
 
Genomics May Provide New Insight Into Bladder Cancer Treatments
Michelle Dalton
 
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)
Robert J. Motzer, Naomi B. Haas, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae-Lyun Lee, Bohuslav Melichar, Brian I. Rini, Toni K. Choueiri, Milada Zemanova, Lori A Wood, Dirk Fahlenkamp, Martin Neil Reaume, Arnulf Stenzl, Weichao Bao, Paola Aimone, Christian Doehn, Paul Russo, Cora N. Sternberg
 -1
Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis
Nizar M. Tannir, Camillo Porta, Viktor Gruenwald, Toni K. Choueiri, Qasim Ahmad, Marlene Carrasco Alfonso, Luca Dezzani, Jackie Han, Cora N. Sternberg
 
KEYNOTE-045: Pembrolizumab Maintains Overall Survival Benefit in Urothelial Cancer
Debra Gordon
 
Comparison of clinical outcomes with IMRT and proton therapy for prostate cancer
Nancy P. Mendenhall, William Wong, Curtis Bryant, Sujay A. Vora, Randal H. Henderson, Sameer R. Keole, Bradford S. Hoppe, Carlos E. Vargas, R. Charles Nichols, Thomas Backus Daniels, William M. Mendenhall, Christopher G. Morris, Steven E. Schild
 
SCHVÁLENÍ PŘÍPRAVKU KEYTRUDA® (PEMBROLIZUMAB) PRO LÉČBU PACIENTŮ S LOKÁLNĚ POKROČILÝM NEBO METASTAZUJÍCÍM UROTELIÁLNÍM KARCINOMEM
 
Aktuální výsledky klinických studií
Katarína Petráková
 
Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer
Dave Levitan
 
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
Mark E. Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine M. Tung, Anne Armstrong, Wenting Wu, Carsten Dietrich Goessl, Sarah Runswick, Pier Franco Conte
 
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
Richard S. Finn, John Crown, Istvan Lang, Katalin Boer, Igor Bondarenko, Sergey O. Kulyk, Johannes Ettl, Ravindranath Patel, Tamas Pinter, Marcus Schmidt, Yaroslav V. Shparyk, Anu Thummala, Nataliya L. Voytko, Camilla Fowst, Xin Huang, Sindy Kim, Dennis J. Slamon
 
Pertuzumab Reduced Risk of Invasive Disease–Free Survival Compared With Placebo in APHINITY
Michelle Dalton
 
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)
Gunter Von Minckwitz, Marion Jennifer Procter, Evandro De Azambuja, Dimitrios Zardavas, Adam Knott, Giuseppe Viale, Thomas M. Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark, Mark Benyunes, Istvan Lang, Christelle Levy, Denise A. Yardley, Jose Bines, Richard D. Gelber, Martine J. Piccart-Gebhart, Jose Baselga
 
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).
Luca Malorni, Giuseppe Curigliano, Alessandro Marco Minisini, Saverio Cinieri, Carlo Tondini, Grazia Arpino, Lorenzo Pavesi, Angelo Martignetti, Carmen Criscitiello, Fabio Puglisi, Marta Pestrin, Giuseppina Sanna, Erica Moretti, Emanuela Risi, Chiara Biagioni, Luca Boni, Daniela Baldari, Marc E. Buyse, Laura Biganzoli, Angelo Di Leo
 
Phase II study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A
Sylvia Adams, Peter Schmid, Hope S. Rugo, Eric P. Winer, Delphine Loirat, Ahmad Awada, David W. Cescon, Hiroji Iwata, Mario Campone, Rita Nanda, Rina Hui, Giuseppe Curigliano, Deborah Toppmeyer, Joyce O‘Shaughnessy, Sherene Loi, Shani Paluch-Shimon, Deborah Card, Jing Zhao, Vassiliki Karantza, Javier Cortes
 
A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03)
Mette S. Van Ramshorst, Erik van Werkhoven, Ingrid A. Mandjes, Inge Kemper, Vincent O. Dezentjé, Irma M. Oving, Aafke H. Honkoop, Lidwine W Tick, Agnes W Van de Wouw, Caroline M Mandigers, Jelle Wesseling, Marie-Jeanne Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke
 
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER
Pier Franco Conte, Giancarlo Bisagni, Antonio Frassoldati, Alba Ariela Brandes, Elisa Anselmi, Francesco Giotta, Michele Aieta, Vittorio Gebbia, Antonino Musolino, Ornella Garrone, Cristiana Taverniti, Giovanna Cavazzini, Anna Turletti, Daniela Rubino, Elisa Picardo, Antonella Ferro, Federico Piacentini, Sara Balduzzi, Roberto D‘Amico, Valentina Guarneri
 
NOVINKY Z ASCO – GYNEKOLOGICKÉ MALIGNITY
Michal Zikán
 
LION Findings Endorse Omitting Lymphadenectomy in Node-Negative Advanced Ovarian Cancer
Kara Nyberg
 
LION: Lymphadenectomy in ovarian neoplasms – A prospective randomized AGO study group led gynecologic cancer intergroup trial
Philipp Harter, Jalid Sehouli, Domenica Lorusso, Alexander Reuss, Ignace Vergote, Christian Marth, Jae Weon Kim, Francesco Raspagliesi, Boern Lampe, Fabio Landoni, Werner Meier, David Cibula, Alexander Mustea, Sven Mahner, Ingo B. Runnebaum, Barbara Schmalfeldt, Alexander Burges, Rainer Kimmig, Uwe A. G. Wagner, Andreas Du Bois
 
No Increase in Recurrence-Free Survival with Combined Regimen for Stage III/IVA Endometrial Cancer
Kathy Holliman
 
A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma
Daniela Matei, Virginia L. Filiaci, Marcus Randall, Margaret Steinhoff, Paul DiSilvestro, Katherine M. Moxley, Byoung Kim, Matthew A. Powell, David M. O‘Malley, Nicola M. Spirtos, Krishnansu Sujata Tewari, Wm Edward Richards, John Nakayama, David Gardner Mutch, David S. Miller
 
Trend in OS Benefit with Cediranib for Ovarian Cancer: ICON6 Results
Kathy Holliman
 
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer
Jonathan A. Ledermann, Andrew C. Embleton, Timothy Perren, Gordon C. Jayson, Gordon J. S. Rustin, Stanley B. Kaye, Hal W. Hirte, Amit M. Oza, Michelle Margaret Vaughan, Michael Friedlander, Antonio Gonzalez Martin, Elizabeth Clark, Babasola O Popoola, Laura Farrelly, Ann Marie Swart, Adrian Cook, Richard S. Kaplan, Mahesh KB Parmar, ICON6 Collaborators
 
Chemotherapy Added to RT Prolongs FFS in Stage III Endometrial Cancer
Debra Gordon
 
Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer
Stephanie M. De Boer, Melanie E. Powell, Linda R. Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B Ottevanger, Jonathan A. Ledermann, Pearly Khaw, Alessandro Colombo, Anthony W. Fyles, Marie-Helene Baron, Henry C. Kitchener, Hans Nijman, Roy F.P.M. Kruitwagen, Ina M. Jurgenliemk-Schulz, Remi A. Nout, Vincent T.H.B.M. Smit, Hein Putter, Carien L. Creutzberg, PORTEC Study Group
 
NOVINKY Z LETOŠNÍHO SETKÁNÍ AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Milada Zemanová
 
Education Session Reviews Current Management of Early-Stage NSCLC, Offers Glimpse of Future Advances
Kara Nyberg
 
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)
Tom Stinchcombe, Rolf A. Stahel, Lukas Bubendorf, Philip Bonomi, Augusto E. Villegas, Dariusz Kowalski, Christina S. Baik, Dolores Isla, Javier De Castro, Pilar Garrido Lopez, Achim Rittmeyer, Marcello Tiseo, Sven Franz Stanzel, Sanne de Haas, Lisa Lam, Michael Lu, Solange Peters
 
Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)
Mark M. Awad, Giulia Costanza Leonardi, Sasha Kravets, Suzanne Eleanor Dahlberg, Alexander E. Drilon, Sinead Noonan, D. Ross Camidge, Sai-Hong Ignatius Ou, Daniel Botelho Costa, Shirish M. Gadgeel, Conor Ernst Steuer, Patrick M. Forde, Viola Weijia Zhu, Yoko Korenaga Fukuda, Jeffrey W. Clark, Pasi A. Janne, Tony Mok, Lynette M. Sholl, Rebecca Suk Heist
 
PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC)
Joshua K. Sabari, Joseph Montecalvo, Ruqin Chen, Jordan A. Dienstag, Chebli Mrad, Isabella Bergagnini, Wei-Chu Victoria Lai, Kathryn Cecilia Arbour, Catherine A. Shu, Matthew David Hellmann, Gregory J. Riely, Mark G. Kris, Charles M. Rudin, Natasha Rekhtman, Alexander E. Drilon
 
VÝBĚR ZE ZAJÍMAVÝCH PŘEDNÁŠEK A POSTERŮ ZE SEKCE MELANOM
Ivana Krajsová
 
Combined Checkpoint Inhibition Ushers in a New Era of CNS Therapy in Melanoma
Kara Nyberg
 
Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204
Hussein Abdul-Hassan Tawbi, Peter A. J. Forsyth, Alain Patrick Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Rene Gonzalez, Christopher D. Lao, Michael Andrew Postow, Michael B. Atkins, Marc S. Ernstoff, Igor Puzanov, Ragini Reiney Kudchadkar, Reena Parada Thomas, Ahmad A. Tarhini, Joel Jiang, Alexandre Avila, Sheena Demelo, Kim Allyson Margolin
 
A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC)
Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, Serigne Lo, Alexander David Guminski, Michael Paul Brown, Maria Magdalena Gonzalez, Katrina Diamante, Shahneen Kaur Sandhu, Richard A. Scolyer, Louise Emmett, Grant A. McArthur
 

Tiráž

Vydavatelství: We Make Media, s. r. o. | Jednatelka: MUDr. Ivana Kaderková | Adresa: Italská 24, 120 00 Praha 2, Česká republika | Tel.: +420 778 476 475 | E-mail: info@wemakemedia.cz | www.wemakemedia.cz
Odpovědná redaktorka: PhDr. Jana Vytlačilová | Jazyková redaktorka: PhDr. Hana Kaiserová
Zlom a grafická úprava: We Make Media, s. r. o. | ISBN: 978 – 80 – 87339 – 31 – 2 | Vyšlo: září 2017

Jakékoliv kopírování a šíření celého obsahu nebo jeho části, a to ať v tištěné, nebo v elektronické formě je bez souhlasu vydavatelství zakázáno.
Vychází 1 x ročně | 3. ročník | V publikaci byly s povolením Americké společnosti klinické onkologie použité texty a fotografie ze zdroje:
http://am.asco.org. Texts and photos from the source http://am.asco.org are used with permission of the American Society of Clinical Oncology.
All rights reserved. © 2017 American Society of Clinical Oncology.



Komerce

Partneři projektu